Skip to main content

Table 3 Effects of TNF-α inhibitor treatment on lipid profile

From: Effects of anti-TNF-α treatment on lipid profile in rheumatic diseases: an analytical cohort study

 

Time

Baseline value before treatment

0–6 months

6–12 months

12–18 months

18–24 months

Total cholesterol (mg/dl)

Mean ± standard error

180.85 ± 2.12

188.12 ± 2.35

183.80 ± 2.14

184.48 ± 2.08

184.88 ± 2.09

p value

 

<0.0001

NS

0.030

0.015

Multivariate modela

p value

 

0.018

NS

0.041

0.018

HDL (mg/dl)

Mean ± standard error

51.8 ± 1.07

53.55 ± 1.21

51.06 ± 1.13

52.04 ± 1.18

52.05 ± 1.18

p value

 

NS

NS

NS

NS

Multivariate modela

p value

 

NS

NS

NS

NS

LDL (mg/dl)

Mean ± standard error

108.70 ± 1.55

109.00 ± 1.92

108.42 ± 1.76

108.54 ± 1.75

108.67 ± 1.70

p value

 

NS

NS

NS

NS

Multivariate modela

p value

 

NS

NS

NS

NS

Triglycerides (mg/dl)

Mean ± standard error

116.00 ± 3.55

132.02 ± 4.63

124.47 ± 3.95

128.72 ± 4.17

129.36 ± 4.32

p value

 

<0.0001

0.005

<0.0001

<0.0001

Multivariate modela

p value

 

<0.0001

0.004

<0.0001

<0.0001

Atherogenic index (LogTG/HDL)

Mean ± standard error

–0.032 ± 0.017

–0.001 ± 0.02

–0.01 ± 0.019

0.009 ± 0.018

0.004 ± 0.019

p value

 

0.005

0.043

0.001

0.003

Multivariate modela

p value

 

0.007

0.04

0.001

0.004

  1. aAdjusted for hyperlipidemia, statin treatment, steroid treatment, rheumatic diseases (RA, AS, PsA), obesity, smoking, diabetes, hypertension, ischemic heart disease, gender, and age
  2. TNF-α tumor necrosis factor alpha, HDL high-density lipoprotein, LDL low-density lipoprotein, TG, triglycerides, NS not significant, RA rheumatoid arthritis, AS ankylosing spondylitis, PsA psoriatic arthritis